KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer

Basit Öğe Kaydı
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorTaştekin, Ebru
dc.contributor.authorErdoğan, Bülent
dc.contributor.authorHacıbekiroğlu, İlhan
dc.contributor.authorTozkır, Hilmi
dc.contributor.authorGürkan, Hakan
dc.contributor.authorÇiçin, İrfan
dc.date.accessioned2021-11-20T10:10:03Z
dc.date.available2021-11-20T10:10:03Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Anabilim Dalıen_US
dc.description.abstractBackground: Lung cancer is one of the most lethal cancers. It is mainly classified into 2 groups: non-small cell lung can-cer (NSCLC) and small cell lung cancer (SCLC). Extrapul-monary small cell carcinomas (EPSCC) are very rare. The Ras oncogene controls most of the cellular functions in the cell. Overall, 21.6% of human cancers contain a Kirsten Ras (KRAS) mutation. SCLC and EPSCC have several similar features but their clinical course is different.Aims: We investigated the KRAS mutation status in SCLC and EPSCC.Study design: Mutation research.Methods: Thirty-seven SCLC and 15 EPSCC patients were included in the study. The pathological diagnoses were confirmed by a second pathologist. KRAS analysis was performed in our medical genetic department. DNA isola-tion was performed with primary tumor tissue using the QIAamp DNA FFPE Tissue kit (Qiagen; Hilden, Germany) in all patients. The therascreen KRAS Pyro Kit 24 V1 (Qia-gen; Hilden, Germany) was used for KRAS analyses. Results: Thirty-four (91.9%) of the SCLC patients were male, while 11 (73.3%) of the EPSCC l patients were fe-male. SCLC was more common in males, and EPSCC in females (p=0.001). A KRAS mutation was found in 6 (16.2%) if SCLC patients. The most common mutation was Q61R (CAA>CGA). Among the 15 EPSCC patients, 2 had a KRAS mutation (13.3%). When KRAS mutant and wild type patients were compared in the SCLC group, no differ-ence was found for overall survival (p=0.6).Conclusion: In previous studies, the incidence of KRAS mutation in SCLC was 1-3%; however, it was 16.2% in our study. Therefore, there may be ethnic and geographical differences in the KRAS mutations of SCLC. As a result, KRAS mutation should not be excluded in SCLCen_US
dc.identifier.doi10.5152/balkanmedj.2016.150610en_US
dc.identifier.endpage410en_US
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.issue4en_US
dc.identifier.pmid27606136en_US
dc.identifier.scopus2-s2.0-84979941524en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage407en_US
dc.identifier.trdizinid201250en_US
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TWpBeE1qVXdNQT09
dc.identifier.urihttps://hdl.handle.net/20.500.14551/5486
dc.identifier.volume33en_US
dc.identifier.wosWOS:000383206400006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofBalkan Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240608_ID_Qen_US
dc.subjectCerrahien_US
dc.titleKRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5486.pdf
Boyut:
348.18 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Balkan Medical Journal
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu